用户名: 密   码:
注册 | 忘记密码?
药品详细

Felodipine (非洛地平 )

化学结构式图
中文名
非洛地平
英文名
Felodipine
分子式
Not Available
化学名
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
分子量
Average: 384.254
Monoisotopic: 383.069113515
CAS号
72509-76-3
ATC分类
C08C 未知
药物类型
small molecule
阶段
商品名
Agon;AGON SR;Feloday;Felodur ER;Felogard;Flodil;Hydac;Lexxel;Modip;Munobal;Munobal Retard;Penedil;Perfudal;Plandil;Plendil (AstraZeneca);Plendil Depottab (AstraZeneca);Plendil ER (AstraZeneca);Plendil Retard (AstraZeneca);Preslow;Prevex;Renedil;Splendil;
同义名
Dl-Felodipine;Felodipina [INN-Spanish];felodipine;Felodipine [Usan:Ban:Inn];Felodipinum [INN-Latin];
基本介绍

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

生产厂家
  • Astrazeneca pharmaceuticals lp
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
封装厂家
参考
Synthesis Reference Not Available
General Reference
  1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. Pubmed
剂型
Form Route Strength
Tablet, extended release Oral 10 mg
Tablet, extended release Oral 2.5 mg
Tablet, extended release Oral 5 mg
规格
Unit description Cost Unit
Plendil 10 mg 24 Hour tablet 3.17 USD tablet
Plendil er 10 mg tablet 3.05 USD tablet
Plendil 10 mg tablet sa 2.96 USD tablet
Felodipine 10 mg 24 Hour tablet 2.95 USD tablet
Plendil er 2.5 mg tablet 2.94 USD tablet
Felodipine er 10 mg tablet 2.72 USD tablet
Plendil er 5 mg tablet 2.6 USD tablet
Plendil 5 mg 24 Hour tablet 1.77 USD tablet
Plendil 2.5 mg 24 Hour tablet 1.76 USD tablet
Felodipine 5 mg 24 Hour tablet 1.67 USD tablet
Plendil 2.5 mg tablet sa 1.65 USD tablet
Plendil 5 mg tablet sa 1.65 USD tablet
Felodipine 2.5 mg 24 Hour tablet 1.57 USD tablet
Felodipine er 2.5 mg tablet 1.51 USD tablet
Felodipine er 5 mg tablet 1.51 USD tablet
Renedil 10 mg Extended-Release Tablet 1.22 USD tablet
Plendil 10 mg Extended-Release Tablet 1.15 USD tablet
Renedil 5 mg Extended-Release Tablet 0.81 USD tablet
Plendil 5 mg Extended-Release Tablet 0.77 USD tablet
Sandoz Felodipine 10 mg Extended-Release Tablet 0.73 USD tablet
Renedil 2.5 mg Extended-Release Tablet 0.6 USD tablet
Plendil 2.5 mg Extended-Release Tablet 0.57 USD tablet
Sandoz Felodipine 5 mg Extended-Release Tablet 0.48 USD tablet
化合物类型
Type small molecule
Classes
  • Dihydropyridines
  • Carboxylic Acids and Derivatives
  • Benzene and Derivatives
  • Halobenzenes
Substructures
  • Dihydropyridines
  • Carboxylic Acids and Derivatives
  • Acetates
  • Ethers
  • Benzene and Derivatives
  • Aryl Halides
  • Halobenzenes
  • Enamines
  • Heterocyclic compounds
  • Aromatic compounds
适应症
ANTIHYPERTENSIVES 降血压;
药理
Indication For the treatment of mild to moderate essential hypertension.
Pharmacodynamics Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.
Mechanism of action Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.
Absorption Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.
Volume of distribution
  • 10 L/kg
Protein binding 99%, primarily to the albumin fraction.
Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

Enzyme Metabolite Reaction Km Vmax
Cytochrome P450 3A4 dehydrofelodipine oxidation 26.4 103.58
Route of elimination Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.
Half life 17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.
Clearance
  • 0.8 L/min [Young healthy subjects]
Toxicity Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD50 is 1050 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
Pathway Name SMPDB ID
Smp00377 Felodipine Pathway SMP00377
理化性质
Properties
State solid
Melting point 145oC
Experimental Properties
Property Value Source
water solubility 19.7 mg/L PhysProp
logP 3.8 PhysProp
Caco2 permeability -4.64 [ADME Research, USCD] BiGG
Predicted Properties
Property Value Source
water solubility 7.15e-03 g/l ALOGPS
logP 4.36 ALOGPS
logP 3.44 ChemAxon Molconvert
logS -4.73 ALOGPS
pKa ChemAxon Molconvert
hydrogen acceptor count 3 ChemAxon Molconvert
hydrogen donor count 1 ChemAxon Molconvert
polar surface area 64.63 ChemAxon Molconvert
rotatable bond count 6 ChemAxon Molconvert
refractivity 99.20 ChemAxon Molconvert
polarizability 38.04 ChemAxon Molconvert
药物相互作用
Drug Interaction
Amobarbital The barbiturate, amobarbital, decreases the effect of felodipine.
Aprobarbital The barbiturate, aprobarbital, decreases the effect of felodipine.
Butabarbital The barbiturate, butabarbital, decreases the effect of felodipine.
Butalbital The barbiturate, butalbital, decreases the effect of felodipine.
Butethal The barbiturate, butethal, decreases the effect of felodipine.
Carbamazepine Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed.
Dihydroquinidine barbiturate The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine.
Erythromycin Erythromycin increases the effect of felodipine
Ethotoin The hydantoin decreases the effect of felodipine
Fosphenytoin The hydantoin decreases the effect of felodipine
Heptabarbital The barbiturate, heptabarbital, decreases the effect of felodipine.
Hexobarbital The barbiturate, hexobarbital, decreases the effect of felodipine.
Itraconazole Itraconazole may increase the therapeutic and adverse effects of felodipine.
Josamycin Erythromycin increases the effect of felodipine
Mephenytoin The hydantoin decreases the effect of felodipine
Methohexital The barbiturate, methohexital, decreases the effect of felodipine.
Methylphenobarbital The barbiturate, methylphenobarbital, decreases the effect of felodipine.
Nelfinavir Nelfinavir increases the effect and toxicity of felodipine
Oxcarbazepine Oxcarbazepine decreases the levels of felodipine
Pentobarbital The barbiturate, pentobarbital, decreases the effect of felodipine.
Phenobarbital The barbiturate, phenobarbital, decreases the effect of felodipine.
Phenytoin The hydantoin decreases the effect of felodipine
Primidone The barbiturate, primidone, decreases the effect of felodipine.
Quinidine barbiturate The barbiturate, quinidine barbiturate, decreases the effect of felodipine.
Quinupristin This combination presents an increased risk of toxicity
Secobarbital The barbiturate, secobarbital, decreases the effect of felodipine.
Tacrolimus Felodipine increases tacrolimus levels
Talbutal The barbiturate, talbutal, decreases the effect of felodipine.
Telithromycin Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed.
Thiopental The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed.
Tipranavir Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine.
Treprostinil Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Tretinoin The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed.
Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed.
食物相互作用
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

返回 | 收藏